Hyperthyroidism News and Research

RSS

Hyperthyroidism is a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs. It is sometimes called thyrotoxicosis, the technical term for too much thyroid hormone in the blood. About 1 percent of the U.S. population has hyperthyroidism. Women are much more likely to develop hyperthyroidism than men.

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New research suggests link between PFAS chemicals and hyperthyroidism in pet cats

New research suggests that there may be a link between higher levels of per- and polyfluoroalkyl substances in the environment and higher levels of hyperthyroidism in pet cats as they age. The findings are published in

20 Sep 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

SNMMI recognizes contributions to nuclear medicine and molecular imaging at 2017 annual meeting

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization, recognized contributions to the field of nuclear medicine and molecular imaging during its 2017 Annual Meeting in Denver, Colorado. Several awards ceremonies were held to recognize the valuable role SNMMI members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions.

2 Aug 2017

IBS researchers devise nanochannels for iodide transport in cell membranes

Exchange of iodide (iodine ions) between bloodstream and cells is crucial for the health of several organs and its malfunctioning is linked to goiter, hypo- and hyperthyroidism, breast cancer, and gastric cancer.

8 Jun 2017

IBS scientists uncover biological pathway that contributes to thyroid disorder

A team led by KOH Gou Young, director of the Center for Vascular Research, within the Institute for Basic Science, in collaboration with Chungnam National University, clarified the molecular mechanism to explain how the thyroid and surrounding vascular system change in the most common form of hyperthyroidism.

18 May 2017

Breakthrough therapy reduces symptoms of Graves' eye disease in clinical trials

The disease is characterized by inflammation and a buildup of tissue around the eyes that cause them to bulge painfully from their sockets.

4 May 2017

New report shows how to manage patients with obesity by prescribing optimal medications

While diet, exercise and behavior modification are essential components of obesity management, a successful long-term weight loss strategy should also include avoiding or minimizing medication-related weight gain, according to a new report from Weill Cornell Medicine.

14 Feb 2017

New minimally invasive approach to diagnose hyperparathyroidism

Almost all of us have four parathyroid glands, located next to the thyroid gland in the neck. They are an organ only the size of a grain of rice, but critical for controlling our body's calcium levels.

24 Oct 2016

ATA announces winner of John B. Stanbury Thyroid Pathophysiology Medal

The American Thyroid Association will present the John B. Stanbury Thyroid Pathophysiology Medal to Kenneth D. Burman, M.D. at the ATA's 86th Annual Meeting, September 21-25, 2016, in Denver, Colorado.

21 Sep 2016

New ATA recommendations offer guidance for managing all forms of thyrotoxicosis

New evidence-based recommendations from the American Thyroid Association provide guidance to clinicians in the management of patients with all forms of thyrotoxicosis (excessively high thyroid hormone activity), including hyperthyroidism.

18 Aug 2016

Researchers find gene variants that predict adverse effects of hyperthyroidism drugs

Researchers and doctors at Uppsala University, along with Swedish and international collaboration partners, have found gene variants that predict the risk of a serious adverse reaction to drugs used for the treatment of hyperthyroidism. The results are published in The Lancet Diabetes & Endocrinology.

4 May 2016

Finding may aid in the design of potential therapies for thyroid problems

Thyroid disease affects about 12 percent of the U.S. population. While many people with thyroid disease don't even know they have it, an overactive or underactive thyroid can cause a slew of problems, including weight gain or loss, mood changes and infertility. In children, an underactive thyroid can be fatal, which is why they are tested for a deficiency at birth.

11 Jan 2016

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015